Title
Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy
UMMS Affiliation
UMass Center for Clinical and Translational Science
Publication Date
2013-12-01
Document Type
Article
Disciplines
Immunology and Infectious Disease | Infectious Disease | Maternal and Child Health | Pediatrics | Translational Medical Research | Virus Diseases
Abstract
OBJECTIVE: To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth. METHODS: The study population included HIV-uninfected live-born singleton infants of mothers enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 (born 2002-2011) in the United States and exposed in utero to a combined (triple or more) antiretroviral regimen. Infant weight at birth and 6 months was compared between infants exposed and unexposed to tenofovir in utero using 2-sample t test, chi test, and multivariable linear and logistic regression models, including demographic and maternal characteristics. RESULTS: Among 2025 infants with measured birth weight, there was no difference between those exposed (N = 630, 31%) versus unexposed to tenofovir in mean birth weight (2.75 vs. 2.77 kg, P = 0.64) or mean gestational age- and sex-adjusted birth weight z-score (WASZ) (0.14 vs. 0.14, P = 0.90). Among 1496 infants followed for 6 months, there was no difference in mean weight at 6 months between tenofovir-exposed (N = 457, 31%) and tenofovir-unexposed infants (7.64 vs. 7.59 kg, P = 0.52) or in mean WASZ (0.29 vs. 0.26, P = 0.61). Tenofovir exposure during the second/third trimester, relative to no exposure, significantly predicted underweight (WASZ < 5%) at age 6 months [odds ratio (95% confidence interval): 2.06 (1.01 to 3.95), P = 0.04]. Duration of tenofovir exposure did not predict neonatal or infant growth. CONCLUSIONS: By most measures, in utero exposure to tenofovir did not significantly predict infant birth weight or growth through 6 months of age.
Keywords
tenofovir, mother-to-child transmission, infant growth, TDF, HIV, pregnancy, UMCCTS funding
DOI of Published Version
10.1097/QAI.0b013e3182a7adb2
Source
J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):374-81. doi: 10.1097/QAI.0b013e3182a7adb2. Link to article on publisher's site
Journal/Book/Conference Title
Journal of acquired immune deficiency syndromes (1999)
Related Resources
PubMed ID
24169122
Repository Citation
Ransom, Carla E.; Huo, Yanling; Patel, Kunjal; Scott, Gwendolyn B.; Watts, Heather D.; Williams, Paige; Siberry, George K.; Livingston, Elizabeth G.; and P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group, "Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy" (2013). UMass Center for Clinical and Translational Science Supported Publications. 194.
https://escholarship.umassmed.edu/umccts_pubs/194
Comments
The UMass Center for Clinical and Translational Science was a participating site for this study: 7301 WNE Maternal Pediatric Adolescent AIDS CRS (Sharon Cormier, RN; Katherine Luzuriaga, MD; Supported by CTSA Grant Number: 8UL1TR000161).